Evaxion Biotech A/S Stock Scheduled to Reverse Split on Monday, January 13th (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock is going to reverse split on Monday, January 13th. The 1-5 reverse split was announced on Monday, December 30th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 10th.

Evaxion Biotech A/S Price Performance

EVAX stock opened at $0.89 on Thursday. The stock has a market capitalization of $5.22 million, a price-to-earnings ratio of -3.07 and a beta of -0.39. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 52-week low of $0.83 and a 52-week high of $13.61. The stock’s fifty day simple moving average is $1.47 and its 200-day simple moving average is $2.43.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. Equities research analysts expect that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.